^
Association details:
Biomarker:No biomarker
Cancer:Colorectal Cancer
Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
Cotellic (cobimetinib) (MEK1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
...for the treatment of advanced CRC include sunitinib plus FOLFIRI, cetuximab plus brivanib, erlotinib plus bevacizumab, cediranib plus FOLFOX/CAPEOX, and atezolizumab plus cobimetinib. These regimens are not recommended for the treatment of patients with CRC.